Shannon Heaning, Content Associate

Oyetewa Asemba, MD, discussed common mistakes in hair loss and pigmentary disorder care, from scalp exams to treatment vehicle selection.

Eileen Cheever, PA, discussed family hesitancy toward systemic pediatric psoriasis treatment and age-related treatment gaps in dermatology.

Test your knowledge of GPP recognition, clinical presentation, complications, and targeted treatment!

Victoria Garcia-Albea, NP, discussed the learning curve dermatology NP fellows experience and the need for greater dermatology education for APPs.

An MCC case illustrates how travel distance and limited oncology access can influence treatment decisions and adherence in rural patients.

Aaron Farberg, MD, discusses Isoclear’s 3-phase approach to acne treatment, from active breakouts to long-term skin maintenance.

Lisa Swanson, MD, FAAD, discussed expanding oral JAK inhibitor options for younger children with atopic dermatitis and alopecia areata.

Envudeucitinib achieved PASI 100 in 54% of continuously treated patients at 48 weeks in the phase 3 ONWARD3 extension study.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Eileen Cheever, PA, discussed how understanding immunologic pathways can strengthen patient counseling and treatment confidence in dermatology.

Sonelokimab met the primary end point in phase 3 IZAR-1, with 42.1% of biologic-naive patients achieving ACR50 at week 16.

Stay ahead with a weekly roundup of the biggest practice management, AI, policy, business, and professional development updates in dermatology.

Isoclear regimen combines topical isotretinoin with stage-specific ingredients from active treatment through long-term maintenance

Aaron Farberg, MD, discusses how localized isotretinoin delivery may affect treatment burden, tolerability, and adherence.

Kimberly Madison, DNP, and Jade Trevino, BSN, RN, discussed nurse-led triage, task shifting, and AI-supported care models for expanding dermatology access in a recent Dermatology Times interview.

Madison and Trevino discuss how AI can support diagnostic decisions, improve efficiency, and strengthen NP-led dermatology care

AAD guidelines strongly recommend roflumilast, ruxolitinib, and tapinarof, expanding steroid-sparing options for pediatric atopic dermatitis.

Catch up on the biggest clinical updates, expert insights, and exclusive interviews from Elevate-Derm Summer 2026 in San Diego, California.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Catch Up on Coverage From Day 5 of the 3rd Annual Elevate-Derm Summer Conference

Catch Up on Coverage From Day 4 of the 3rd Annual Elevate-Derm Summer Conference

Catch Up on Coverage From Day 3 of the 3rd Annual Elevate-Derm Summer Conference

Faculty at Elevate-Derm Summer 2026 discussed the expanding role of oral JAK inhibitors in pediatric dermatology, emphasizing earlier intervention, individualized patient selection, safety monitoring, and family-centered counseling.

Advances in vitiligo, hidradenitis suppurativa, and hair loss were among the key trends Chantel Hillstead, APRN, said APPs should watch.

Lisa Swanson, MD, discussed strategies for counseling patients on JAK inhibitor safety and where she sees the drug class expanding next in a recent Dermatology Times interview.

Oyetewa Asempa, MD, discussed the importance of scalp examination, trichoscopy, and culturally informed communication when evaluating patients with hair loss during a recent Dermatology Times interview

Victoria Garcia Albea, NP, discussed safety monitoring, patient selection, and laboratory screening considerations for oral JAK inhibitors at Elevate-Derm summer 2026

Catch Up on Coverage From Day 2 of the 3rd Annual Elevate-Derm Summer Conference

At Elevate Derm, Lisa Swanson, MD, discussed earlier oral JAK inhibitor use for alopecia areata and selecting appropriate patients.

Aaron Farberg, MD, discusses how Isoclear aims to deliver isotretinoin directly to the skin through a customizable compounded topical system while avoiding the monitoring requirements associated with oral therapy.